KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Other financing activities (2017 - 2020)

Historic Other financing activities for Takeda Pharmaceutical (TAK) over the last 4 years, with Q1 2020 value amounting to -$20.1 million.

  • Takeda Pharmaceutical's Other financing activities fell 11012.56% to -$20.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.6 million, marking a year-over-year decrease of 12011.65%. This contributed to the annual value of -$109.3 million for FY2025, which is 3961.97% up from last year.
  • As of Q1 2020, Takeda Pharmaceutical's Other financing activities stood at -$20.1 million, which was down 11012.56% from -$15.5 million recorded in Q2 2019.
  • Takeda Pharmaceutical's 5-year Other financing activities high stood at $25.1 billion for Q4 2017, and its period low was -$21.9 million during Q2 2018.
  • In the last 4 years, Takeda Pharmaceutical's Other financing activities had a median value of -$15.5 million in 2019 and averaged $5.0 billion.
  • Its Other financing activities has fluctuated over the past 5 years, first soared by 2953.44% in 2019, then tumbled by 11012.56% in 2020.
  • Quarter analysis of 4 years shows Takeda Pharmaceutical's Other financing activities stood at $25.1 billion in 2017, then crashed by 100.09% to -$21.9 million in 2018, then rose by 29.53% to -$15.5 million in 2019, then crashed by 30.28% to -$20.1 million in 2020.
  • Its Other financing activities was -$20.1 million in Q1 2020, compared to -$15.5 million in Q2 2019 and $198.9 million in Q1 2019.